SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Celgene Release: REVLIMID® and VIDAZA® Combination Therapy Achieves Nearly 30 Percent Complete Response in Untreated Elderly Patients With Acute Myeloid Leukemia